Grace Therapeutics, Inc.
GRCE
$2.14
$0.020.94%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -34.86% | 30.35% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -20.80% | 22.91% | |||
| Operating Income | 20.80% | -22.91% | |||
| Income Before Tax | -448.64% | -24.32% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -1,240.41% | 49.11% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1,240.41% | 49.11% | |||
| EBIT | 20.80% | -22.91% | |||
| EBITDA | 20.81% | -22.98% | |||
| EPS Basic | -1,238.65% | 50.04% | |||
| Normalized Basic EPS | 21.59% | -22.01% | |||
| EPS Diluted | -1,238.65% | 50.04% | |||
| Normalized Diluted EPS | 21.59% | -22.01% | |||
| Average Basic Shares Outstanding | 0.08% | 1.91% | |||
| Average Diluted Shares Outstanding | 0.08% | 1.91% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||